TRexBio and Retension raise funds in biotech IPOs

TRexBio priced an initial public offering that raised $116.7 million, with a focus on regulatory T cell therapies. Retension also made a $45 million Nasdaq debut tied to hypertension. The offerings suggest sustained investor appetite for biotech, aided by Eli Lilly and Nobel Prize-winning science.

Two biotech companies have raised money through public listings. TRexBio priced an initial public offering that brought in $116.7 million and centers on regulatory T cell therapies. Retension made a $45 million Nasdaq debut linked to hypertension. The offerings are described as evidence of continued investor appetite for biotech, with Eli Lilly and Nobel Prize-winning science cited as supportive factors. The available material does not include further specifics about either company’s programs, financial terms, or investors.